A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial.
Ebiomedicine
Hoyer, K K; Hablesreiter, R R; Inoue, Y Y; Yoshida, K K; Briest, F F; Christen, F F; Kakiuchi, N N; Yoshizato, T T; Shiozawa, Y Y; Shiraishi, Y Y; Striefler, J K JK; Bischoff, S S; Lohneis, P P; Putter, H H; Blau, O O; Keilholz, U U; Bullinger, L L; Pelzer, U U; Hummel, M M; Riess, H H; Ogawa, S S; Sinn, M M; Damm, F F
Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma.
The Journal Of Pathology. Clinical Research
Köbel, Martin M; Piskorz, Anna M AM; Lee, Sandra S; Lui, Shuhong S; LePage, Cecile C; Marass, Francesco F; Rosenfeld, Nitzan N; Mes Masson, Anne-Marie AM; Brenton, James D JD
Stratification of Wilms tumor by genetic and epigenetic analysis.
Oncotarget
Scott, Richard H RH; Murray, Anne A; Baskcomb, Linda L; Turnbull, Clare C; Loveday, Chey C; Al-Saadi, Reem R; Williams, Richard R; Breatnach, Fin F; Gerrard, Mary M; Hale, Juliet J; Kohler, Janice J; Lapunzina, Pablo P; Levitt, Gill A GA; Picton, Sue S; Pizer, Barry B; Ronghe, Milind D MD; Traunecker, Heidi H; Williams, Denise D; Kelsey, Anna A; Vujanic, Gordan M GM; Sebire, Neil J NJ; Grundy, Paul P; Stiller, Charles A CA; Pritchard-Jones, Kathy K; Douglas, Jenny J; Rahman, Nazneen N